Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Reticulate Micro, Inc. ("Reticulate Micro" or the "Company") , a software products company specializing in advanced video compression and streaming solutions, is pleased to announce its partnership ...

The potential impact of Trump’s suspension of Foreign Corrupt Practices Act (FCPA) enforcement is significant, particularly ...

The asset-backed primary is bracing for another busy week after 16 issuers priced more than US$14.8bn last week, while the RMBS sector is expecting a number of jumbo deals. Over in the ECM, primary ...

An academic study of the merger hopes to give insight into how attorneys general can strengthen certificate-of-need laws and the importance of having more power over sales. Other industry news focuses ...

Highlights,Institutional ownership in Eli Lilly, (NYSE:LLY),has seen an increase, with multiple firms adding to their ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 10 includes Advanced Micro Devices, Novo Nordisk ...